Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28462767 | 0.88 | KMT2A (0.55) | KEAP1CES2KMT2AATMHPGD | |
| SCHEMBL25902696 | 0.87 | CDC25B (0.47) | KEAP1KMT2AATMALDH1A1HPGD | |
| SCHEMBL27637456 | 0.87 | CES2 (0.56) | KEAP1CES2KDM4EALDH1A1HPGD | |
| SCHEMBL3213469 | 0.86 | CES2 (0.48) | KEAP1CES2KMT2AATMCES1 | |
| SCHEMBL29406303 | 0.86 | KEAP1 (0.55) | KEAP1CES2KMT2AKDM4EALDH1A1 | |
| SCHEMBL222474 | 0.86 | KEAP1 (0.55) | KEAP1CES2KMT2AKDM4EALDH1A1 | |
| SCHEMBL8572602 | 0.86 | KEAP1 (0.50) | KEAP1CES2KMT2AATMKDM4E | |
| SCHEMBL679186 | 0.84 | CES2 (0.47) | KEAP1CES2KMT2AATMALDH1A1 | |
| SCHEMBL29789763 | 0.84 | CES2 (0.47) | KEAP1CES2KMT2AATMCES1 | |
| SCHEMBL2074860 | 0.84 | KMT2A (0.49) | CES2KMT2AATMCES1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677472-B | Synthesis method of drug intermediate and application of drug intermediate in synthesis of penconazole | 辽宁大学 | 2024-08-06 | — | — | CN | claimed |
| CN-115677472-A | Synthetic method of drug intermediate and application of drug intermediate in synthesis of chlorofluoromethrin | 辽宁大学 | 2023-02-03 | — | — | CN | claimed |
| CN-111072517-B | Preparation method of 4-amino-2-trifluoromethyl benzonitrile | 常州沃腾化工科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-111072517-A | Preparation method of 4-amino-2-trifluoromethyl benzonitrile | 常州沃腾化工科技有限公司 | 2020-04-28 | — | — | CN | claimed |
| CN-107681052-B | Main group metal complexes as p-dopants for organic electronic matrix materials | 西门子公司 | 2020-03-24 | — | — | CN | claimed |
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-106279114-B | A kind of synthetic method of Taladegib | 东南大学 | 2019-01-29 | — | — | CN | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | KEAP1 1864/4885CES2 1598/4885KMT2A 1624/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | KEAP1 2845/4885CES2 2351/4885KMT2A 826/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | KEAP1 3106/4885CES2 594/4885KMT2A 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.